DIFFERENTIATED APPROACH TO TREATMENT OF OSTEOARTHROSIS IN CARDIOVASCULAR PATHOLOGY
https://doi.org/10.15829/1560-4071-2016-2-84-89
Abstract
Aim. Assessment of clinical efficacy of cutaneous and supravenal cutaneous lowintensive radiation (CLIR) together with parenteral chondroitin sulfate (Chondrogard® ) in osteoarthrosis patients with cardiovascular comorbidities.
Material and methods. Totally, 65 women and 15 men studied, at the age 50,62±8,9 y.o., with knee and hip osteoarthrosis stage I-III by X-ray staging. Patients from treatment group underwent intramuscular Chondrogard® once in 2 days for 2 months, with CLIR, cutaneous and supravenal, and low doses of NSAIDs. Controls received Chondrogard® with common therapy (CT) or only CT.
Results. The significantly better dynamics is shown of the pain syndrome in joint is shown by the results of VAS in points and mm, and BP and HR, comparing to those receiving Chondrogard® and CT, that made to decrease the dosages of NSAIDs and to minimize side effects.
About the Authors
L. V. Vasilieva
N.N. Burdenko Voronezh State Medical University
Russian Federation
Voronezh
Russian Federation
Voronezh
E. F. Evstratova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Voronezh
Russian Federation
Voronezh
A. V. Nikitin
N.N. Burdenko Voronezh State Medical University
Russian Federation
Voronezh
Russian Federation
Voronezh
N. S. Burdina
N.N. Burdenko Voronezh State Medical University
Russian Federation
Voronezh
Russian Federation
Voronezh
V. S. Lednyova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Voronezh
Russian Federation
Voronezh
References
1. Mendel’ OI. Osteoarthritis and cardiovascular diseases. General risk factors and clinikopathogenetic interrelations. Treatment optimization. Profilakticheskaja medicine 2010; (3): 35-41. Russian (Мендель О.И. Остеоартроз и сердечно-сосудистые заболевания. Общие факторы риска и клинико-патогенетические взаимосвязи. Оптимизация лечения. Профилактическая медицина 2010; (3): 35-41).
2. Van Dijk GM. Comorbiditi, limitatations activities and pain in patients with osteoarthritis of the hipor knee. BM Musculoskeletal Dis. 2008; 9: 95.
3. Alekseeva LI, Zajceva EM. Perspective directions of therapy of osteoarthritis. Nauchnoprakticheskaja revmatologija. 2014; 52(3): 247-50. Russian (Алексеева Л. И., Зайцева Е. М. Перспективные направления терапии остеоартроза. Научно-практическая ревматология 2014; 52: 247-50).
4. Badokin VV. Ways of optimization of therapy of osteoarthritis. Russkij medicinskij zhurnal 2006; 14(25): 1824-5. Russian (Бадокин В.В. Пути оптимизации терапии остеоартроза. Русский медицинский журнал 2006; 14.(25): 1824-5).
5. Nasonov EL, Karateev AE. Application of no steroid anti-inflammatory preparations. Clinical recommendations. Russkij medicinskij zhurnal 2006; 14 (25): 1769-77. Russian (Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Практические рекомендации. Русский медицинский журнал 2006; 14. (25): 1769-77).
6. Balabanova RM, Kaptaeva AK. Whether the role of nonsteroid anti-inflammatory preparations during an era of biological agents will change. Russkij medicinskij zhurnal 2006; 14 (4): 278-81. Russian (Балабанова Р.М., Каптаева А.К. Изменится ли роль нестероидных противовоспалительных препаратов в эру биологических агентов. Русский медицинский журнал 2006; (4): 278-81).
7. Evstratova EF. A clinical assessment of efficiency of various methods of pathogenetic therapy of patients with an articulate syndrome with associated diseases of internals. Sistemnyj analyze i upravlenie v biomedicinskih sistemah.2009; 8 (2): 239-42. Russian (Евстратова Е.Ф. Клиническая оценка эффективности различных методов патогенетической терапии больных суставным синдромом с сопутствующими заболеваниями внутренних органов. Системный анализ и управление в биомедицинских системах 2009; 8(2): 239-42).
8. Alekseeva LI. Research of efficiency, shipping and safety of a preparation Hondrogard at patients with osteoarthritis. Farmateka 2013; (7): 60-4. Russian (Алексеева Л. И. Исследование эффективности, переносимости и безопасности препарата Хондрогард у пациентов с остеоартрозом. Фарматека 2013;(7): 60-4).
9. Lazebnik LB, Drozdov VN. Efficiency of a hondroitinsulfat at treatment of a gonartroz and a coxarthrosis at patients of advanced age. Terapevticheskij archive. 2005; (8): 64-9. Russian (Лазебник Л. Б., Дроздов В.Н. Эффективность хондроитинсульфата при лечении гонартроза и коксартроза у больных пожилого возраста. Терапевтический архив 2005; (8): 64-9).
10. Miller L, Peres M, Monfort J, et al. Effectiveness of chondroitin sulfate in concomitant knee osteoarthritis and psoriasis; a randomized, double-blind, placebo-controlled study. OsteoarthrCartil.2010; 18: 32-40.
11. Vallieres M, du Souich P. Modulation of inflammation by chondroitin sulfate OsteoarthrCartil. 2010; 18:1-6.
12. Moskvin SV, Bujlin AV. Bases of laser therapy. M.; Tver: Triada: 2006; 256 p. Russian (Москвин С.В, Буйлин А.В. Основы лазерной терапии. Тверь: Триада, 2006; 256 с).
Review
For citations:
Vasilieva L.V., Evstratova E.F., Nikitin A.V., Burdina N.S., Lednyova V.S. DIFFERENTIATED APPROACH TO TREATMENT OF OSTEOARTHROSIS IN CARDIOVASCULAR PATHOLOGY. Russian Journal of Cardiology. 2016;(2):84-89. (In Russ.) https://doi.org/10.15829/1560-4071-2016-2-84-89
Views:
10232
Email this article 